Search Results for: GNPX

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its plans to participate in two virtual investor conferences in the month of March. These include the Sachs 14th Annual European Life Sciences CEO Forum taking place March 10-12, as well as the 33rd … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for March Investor Conferences”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it has created a Clinical Advisory Board (“CAB”). The company has named world-renowned medical and clinical experts as the board’s first members. The purpose of the board is to provide expert guidance for Genprex’s … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Forms Clinical Advisory Board, Announces $25M Registered Direct Offering”

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it joins with millions of healthcare advocates around the world in support of World Cancer Day. The designation seeks to raise awareness, elevate public understanding of the global cancer burden, promote greater equity and ensure that cancer control … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Joins Millions to Recognize World Cancer Day”

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has issued a shareholder letter and corporate update outlining its developments and initiatives for 2020 and anticipated milestones for 2021 and beyond. “We achieved many significant milestones in 2020 that have set the stage for a transformational 2021,” stated Rodney Varner, … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Issues Shareholder Letter, Corporate Update”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s President and Chief Executive Officer, Rodney Varner, will provide a company overview at the MoneyShow Accredited Investors Virtual Expo taking place virtually January 26-28, 2021. GNPX’s presentation will shine a light … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present Trailblazing Gene Therapies at the MoneyShow Accredited Investors Virtual Expo”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it will present at the upcoming NobleCon17, scheduled for Jan. 19–20, 2021. The virtual event is Noble Capital Markets’ annual investor conference. GNPX’s presentation will include a company overview and address the company’s recent … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present at NobleCon17”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that it has achieved a significant milestone for its REQORSA(TM) Immunogene Therapy. The company has met all specifications and passed all final release tests for its initial scaled-up, clinical-grade manufacturing run of REQORSA(TM) immunogene therapy. This … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Passes Final Release Tests for Manufacturing Run of Proprietary Immunogene Therapy Treatment”

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced the closing of its registered direct offering of 3,116,884 shares of its common stock with a single health care-dedicated institutional investor. Genprex secured gross proceeds of $12 million, before deducting commissions and estimated expenses, with the offering priced at-the-market … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures $12M in Registered Direct Offering”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor. The agreement outlines the purchase and sale of 3,116,884 shares of Genprex common stock; the purchase price of those shares will be $3.85 … Continue reading “QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters into Estimated $12-Million Securities Purchase Agreement”